Promotions & Moves

Provention Bio Appoints Clinical Development SVP

Dr. Kell will lead the PRV-031 program, including the oversight of the Phase III PROTECT study and support of regulatory submissions

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sherron Kell, MD, MPH has been appointed senior vice president of Clinical Development at Provention Bio, Inc., a clinical stage biopharmaceutical company. Dr. Kell will lead the PRV-031 (teplizumab) program, including the oversight of the Phase III PROTECT study and clinical support of anticipated regulatory submissions, and will report to Dr. Eleanor Ramos, chief medical and operating officer. PRV-031 (teplizumab) is an anti-CD3 monoclonal antibody in development for the interception and p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters